ABBVPharmaceuticals
FollowFollowingUnfollowFree · no card
Get what investors say about ABBV next
2 investor calls on ABBV in the last 90 days (2 bullish, 0 bearish). Follow ABBV free and new calls come to you in The Brief, our morning email, the day after we record them. This page shows them a week later.
or continue with Google ·
Who said what, and what ABBV did next
Every dot is a day someone on the record made a call. Hover one to see who. We are not scoring them — the point is that you can see it and judge for yourself.
Who’s talking about ABBV
| Date | Voice | Stance | Venue | Thesis |
|---|---|---|---|---|
| 2026-10-16 | Jason | Bullish | CNBC (uncut) | Revenue diversification across immunology, oncology, and neuroscience replaces Humira patent gap; margin… |
| 2026-10-14 | Jared HolzManaging Director and Healthcare Equity Strategist, Mizuho | Bullish | CNBC (uncut) | AbbVie's pipeline positions it better than most large-cap pharma peers when facing patent-cliff pressure… |
| 2025-08-01 | Scott SchwartzPrincipal, OnePoint BFG Wealth Partners | Bullish | Wealthion | AbbVie is a growth-oriented pharma name that has been indiscriminately sold off alongside the sector on… |
| 2025-02-28 | Jim Lebenthal (Cerity)Partner, Cerity Partners | Bullish | The Compound | AbbVie successfully replaced Humira revenue with Skyrizi and Rinvoq, continues to receive new indications for… |
| 2022-08-19 | Kevin O LearyChairman, O'Leary Ventures | Bullish | CNBC Halftime Committee | AbbVie trades at only 10x earnings due to biosimilar uncertainty, but management can navigate the blockbuster… |
Last reports
| Report | When | EPS actual vs est. | Reaction |
|---|---|---|---|
| 30 Oct 2026 | before the open | 3.82 vs 3.82 | +0.5% |
Notable options days
Sessions in the last 120 where ABBV’s settled options volume ran ≥ 2× its trailing 20-session baseline, or delta-dollar flow ran ≥ 2.5× — 7 of 120 sessions qualified.
| Date | Close | RVOL | Δ$ flow ($M) | Call % | LEAPS % | +20 sess. |
|---|---|---|---|---|---|---|
| 2026-10-14 | ||||||
| 2026-10-07 | ||||||
| 2026-07-16 | ||||||
| 2026-07-14 | ||||||
| 2026-06-25 | ||||||
| 2026-06-23 | ||||||
| 2026-06-22 |
ABBV on the Wheel
ABBV passed our 1-month put test (30-delta put, 30–45 days, sold at the bid, bought back at half the credit), 2021–2026.
The Wheel lists cash-secured puts on stocks after a 3% drop, with live quotes, the chance of assignment and each stock’s own history. Free to use; a free account lets you follow stocks, add your own and ask questions.
Decision support, not advice · questions put sellers ask us
Idea Scout
Following ABBV? Every Sunday we read the tape so you don't have to — who's recommending what, where they agree, and who just changed their mind. One free email a week.
Free · double opt-in · unsubscribe in one click